PL2350090T3 - Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych - Google Patents

Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych

Info

Publication number
PL2350090T3
PL2350090T3 PL09740589T PL09740589T PL2350090T3 PL 2350090 T3 PL2350090 T3 PL 2350090T3 PL 09740589 T PL09740589 T PL 09740589T PL 09740589 T PL09740589 T PL 09740589T PL 2350090 T3 PL2350090 T3 PL 2350090T3
Authority
PL
Poland
Prior art keywords
spiro
therapeutic agents
oxindole compounds
oxindole
compounds
Prior art date
Application number
PL09740589T
Other languages
English (en)
Polish (pl)
Inventor
Mikhail Chafeev
Sultan Chowdhury
Lauren Fraser
Jianmin Fu
Jonathan Langille
Shifeng Liu
Jianyu Sun
Shaoyi Sun
Serguei Sviridov
Mark Wood
Alla Zenova
Qi Jia
Jean-Jacques Cadieux
Simon J Gauthier
Amy Frances Douglas
Tom Hsieh
Nagasree Chakka
Zoran Cikojevic
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41395034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2350090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PL2350090T3 publication Critical patent/PL2350090T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
PL09740589T 2008-10-17 2009-10-13 Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych PL2350090T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10646408P 2008-10-17 2008-10-17
PCT/US2009/060537 WO2010045251A2 (en) 2008-10-17 2009-10-13 Spiro-oxindole compounds and their use as therapeutic agents
EP09740589.8A EP2350090B1 (en) 2008-10-17 2009-10-13 Spiro-oxindole compounds and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
PL2350090T3 true PL2350090T3 (pl) 2015-11-30

Family

ID=41395034

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09740589T PL2350090T3 (pl) 2008-10-17 2009-10-13 Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych

Country Status (30)

Country Link
US (5) US8263606B2 (enExample)
EP (2) EP2350090B1 (enExample)
JP (2) JP5554337B2 (enExample)
KR (1) KR101286323B1 (enExample)
CN (5) CN102256983B (enExample)
AR (1) AR073900A1 (enExample)
AU (1) AU2009303468B2 (enExample)
BR (1) BRPI0920448A2 (enExample)
CA (1) CA2741029A1 (enExample)
CL (1) CL2011000835A1 (enExample)
CY (1) CY1116628T1 (enExample)
DK (1) DK2350090T3 (enExample)
ES (1) ES2546302T3 (enExample)
HK (3) HK1215572A1 (enExample)
HR (1) HRP20150882T1 (enExample)
HU (1) HUE025938T2 (enExample)
IL (2) IL212400A (enExample)
JO (1) JO3032B1 (enExample)
MX (1) MX2011004055A (enExample)
MY (1) MY155255A (enExample)
NZ (1) NZ592275A (enExample)
PE (1) PE20110586A1 (enExample)
PL (1) PL2350090T3 (enExample)
PT (1) PT2350090E (enExample)
RU (1) RU2011119626A (enExample)
SG (2) SG10201703082XA (enExample)
SI (1) SI2350090T1 (enExample)
SM (1) SMT201500206B (enExample)
TW (1) TW201020257A (enExample)
WO (1) WO2010045251A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN101906093B (zh) * 2009-06-05 2013-07-10 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
CN102584860B (zh) * 2011-01-17 2014-12-10 苏州大学 含吲哚结构的螺杂环化合物及其制备方法
US9586964B2 (en) 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2013071201A1 (en) * 2011-11-11 2013-05-16 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
US9012445B2 (en) 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors
KR20150002794A (ko) * 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
CN102838610B (zh) * 2012-08-28 2014-09-10 吕叶叶 双吲哚二氧杂双环辛二酮
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
TW201623264A (zh) 2014-03-29 2016-07-01 魯賓有限公司 作為電位閘控鈉通道調節劑之磺胺化合物
JP6616934B2 (ja) * 2014-05-22 2019-12-04 株式会社 資生堂 レナリドミドの光学分割方法
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
CN107416958A (zh) * 2015-09-17 2017-12-01 温州泓呈祥科技有限公司 去除醇酸树脂车间废水中对二甲苯、邻二甲苯和间二甲苯的方法
PL3356358T3 (pl) 2015-10-02 2020-11-02 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
EP3367798A1 (en) 2015-10-28 2018-09-05 Syngenta Participations AG Microbiocidal oxadiazole derivatives
CN108289448B (zh) 2015-12-02 2021-10-22 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
BR112018014666B1 (pt) * 2016-01-20 2024-01-02 Chemocentryx, Inc Compostos de 2-oxindol, seu uso e composição farmacêutica
WO2017162868A1 (en) 2016-03-24 2017-09-28 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112018070785B1 (pt) 2016-04-12 2023-01-10 Syngenta Participations Ag Compostos derivados de oxadiazol microbiocidas, composição agroquímica, método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos e uso dos referidos compostos
CN109311905A (zh) 2016-06-16 2019-02-05 泽农医药公司 螺-吲哚酮化合物的固态形式
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
AR108745A1 (es) 2016-06-21 2018-09-19 Syngenta Participations Ag Derivados de oxadiazol microbiocidas
US20190284148A1 (en) 2016-07-22 2019-09-19 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
JP2019526535A (ja) 2016-07-22 2019-09-19 シンジェンタ パーティシペーションズ アーゲー 殺微生物オキサジアゾール誘導体
WO2018029242A1 (en) 2016-08-11 2018-02-15 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN106299140A (zh) * 2016-09-21 2017-01-04 广西南宁荣威德新能源科技有限公司 一种新型宽光谱太阳能电池材料
CN109923112A (zh) 2016-09-23 2019-06-21 先正达参股股份有限公司 杀微生物的噁二唑衍生物
PL3522715T3 (pl) 2016-10-06 2021-06-28 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
UY37623A (es) 2017-03-03 2018-09-28 Syngenta Participations Ag Derivados de oxadiazol tiofeno fungicidas
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
US20200187502A1 (en) 2017-03-10 2020-06-18 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3592747A1 (en) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof
CA3055680A1 (en) 2017-03-31 2018-10-04 Syngenta Participations Ag Fungicidal compositions
WO2018177880A1 (en) 2017-03-31 2018-10-04 Syngenta Participations Ag Fungicidal compositions
WO2018185013A1 (en) 2017-04-03 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112019020734B1 (pt) 2017-04-05 2023-12-05 Syngenta Participations Ag Compostos derivados de oxadiazol, composição agroquímica, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos e uso dos referidos compostos
BR112019020739B1 (pt) 2017-04-05 2023-12-19 Syngenta Participations Ag Compostos derivados de oxadiazol microbiocidas e seu uso, composição agroquímica, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos
BR112019020819B1 (pt) 2017-04-05 2023-12-05 Syngenta Participations Ag Composto de fórmula (i), composição agroquímica, método para controlar ou prevenir a infestação de plantas úteis por micro-organismos fitopatogênicos e uso de um composto de fórmula (i)
BR112019021019B1 (pt) 2017-04-05 2023-12-05 Syngenta Participations Ag Compostos derivados de oxadiazol microbiocidas, composição agrícola, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos e uso de um composto derivado de oxadiazol
WO2018184982A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018184984A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018185211A1 (en) 2017-04-06 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN110709395A (zh) 2017-06-02 2020-01-17 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2018219773A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Fungicidal compositions
US20200315176A1 (en) 2017-06-28 2020-10-08 Syngenta Participations Ag Fungicidal compositions
WO2019011929A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
BR112020000465B1 (pt) 2017-07-11 2024-02-20 Syngenta Participations Ag Derivados oxadiazol microbiocidas
WO2019011926A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011928A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
BR112020000371A2 (pt) 2017-07-12 2020-07-14 Syngenta Participations Ag derivados de oxadiazol microbiocidas
WO2019012001A1 (en) 2017-07-12 2019-01-17 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112020000463A2 (pt) 2017-07-13 2020-07-21 Syngenta Participations Ag derivados oxadiazol microbiocidas
CN111356679A (zh) 2017-11-20 2020-06-30 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CN112020503A (zh) 2018-04-26 2020-12-01 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CN108586495B (zh) * 2018-06-12 2020-07-14 广州大学 一种二氟代c2-螺环吲哚啉类化合物及其制备方法
CN112351981A (zh) 2018-06-29 2021-02-09 先正达农作物保护股份公司 杀微生物的噁二唑衍生物
EP3818058A1 (en) 2018-07-02 2021-05-12 Syngenta Crop Protection AG 3-(2-thienyl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as agrochemical fungicides
WO2020011731A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
CN112689631A (zh) 2018-07-16 2021-04-20 先正达农作物保护股份公司 杀微生物的噁二唑衍生物
CN108976243B (zh) * 2018-08-23 2020-03-03 青岛农业大学 通过二甲基呋喃与含氧化吲哚邻羟基苄醇合成螺-色满-4,3′-氧化吲哚的合成方法
CN113195462A (zh) 2018-10-17 2021-07-30 先正达农作物保护股份公司 杀微生物的噁二唑衍生物
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
CN119677724A (zh) 2022-07-21 2025-03-21 先正达农作物保护股份公司 1,2,4-噁二唑杀真菌剂的结晶形式
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma
US11840545B1 (en) * 2023-07-14 2023-12-12 King Faisal University Spirooxindole-copper complex as novel efficient anticorrosion agent for C-steel
CN121568607A (zh) 2023-08-04 2026-02-24 先正达农作物保护股份公司 控制或预防植物被植物病原性微生物多主棒孢菌侵染的方法
CN117736637B (zh) * 2023-10-18 2024-06-11 山东卓高新材料有限公司 一种自修复防水涂料及其制备方法
WO2025256333A1 (en) 2024-06-13 2025-12-18 Syngenta Crop Protection Ag Pesticidally active aminoheterocycle derivatives
WO2025257413A1 (en) 2024-06-13 2025-12-18 Syngenta Crop Protection Ag Pecticidally active dihydroazole derivatives

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) * 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) * 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CH577461A5 (enExample) * 1975-08-13 1976-07-15 Robins Co Inc A H
US4670566A (en) * 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) * 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) * 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) * 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
JP2716986B2 (ja) * 1987-07-17 1998-02-18 シエーリング アクチエンゲゼルシヤフト ９‐ハロゲン‐（ｚ）‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用
JPH0195766A (ja) 1987-10-08 1989-04-13 Tamanoisu Kk 無蒸煮アルコール醪からの食酢の製造法
US5182289A (en) * 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
CA2037923C (en) 1989-07-25 1996-08-06 Taiho Pharmaceutical Co., Ltd. Oxindole derivative
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
EP0558521A1 (en) 1990-11-22 1993-09-08 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives and related spiro compounds with herbicidal action
US5116854A (en) * 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5278162A (en) * 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) * 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) * 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) * 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
CN1047386C (zh) * 1994-04-07 1999-12-15 西玛夫公司 新型褪黑激素拮抗物螺旋[吲哚吡咯烷丁]衍生物,其制备方法及其作为药物产品的用途
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en) * 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
US5972951A (en) 1994-12-22 1999-10-26 Smithkline Beecham Plc Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2235686C (en) 1995-10-24 2007-06-26 Sanofi Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (de) * 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ATE237587T1 (de) * 1997-02-10 2003-05-15 Ono Pharmaceutical Co 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
WO1999033794A1 (en) * 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
JP4087938B2 (ja) * 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
CN1217918C (zh) 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
EP1086101B1 (en) * 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (en) 1998-07-27 2000-02-10 Abbott Laboratories Substituted oxazolines as antiproliferative agents
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
IL144977A0 (en) 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
JP2003505388A (ja) 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
MXPA02000625A (es) * 1999-07-21 2002-07-02 Boehringer Ingelheim Pharma Pequenas moleculas utiles en el tratamiento de enfermedades inflamatorias.
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU1846501A (en) 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US20020045566A1 (en) 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
US6911463B2 (en) * 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
JP2005514366A (ja) * 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
SE0104341D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New use
EP1470126A1 (en) 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
US7659082B2 (en) * 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
MXPA04012418A (es) 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en tratamiento de trastornos de la piel.
JP2005535623A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
CN100558726C (zh) 2003-02-24 2009-11-11 田边三菱制药株式会社 泰妥拉唑的对映体及其在治疗中的应用
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
EP1626722A1 (en) * 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
KR20060009938A (ko) * 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
KR20060037409A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JPWO2005035498A1 (ja) 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
US7507760B2 (en) 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
WO2005097136A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
NZ550222A (en) 2004-04-08 2010-09-30 Topotarget As Diphenyl ox-indol-2-one compounds and their use in the treatment of cancer
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
JP2007536283A (ja) 2004-05-05 2007-12-13 ユニバイオスクリーン エス．アー． ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
MXPA06014573A (es) 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2005287046A1 (en) 2004-09-17 2006-03-30 Bayer Schering Pharma Aktiengesellschaft Processes and intermediates for preparing cysteine protease inhibitors
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CN101166722A (zh) * 2005-04-29 2008-04-23 惠氏公司 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法
US20070072831A1 (en) * 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
EP2032539A4 (en) 2006-06-09 2011-03-16 Merck Sharp & Dohme BENZAZEPINONE AS SODIUM CHANNEL BLOCKER
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
TW200833698A (en) * 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046084A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
BRPI0719166A2 (pt) 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
WO2008046049A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010053998A1 (en) * 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
US20110269788A1 (en) * 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010132352A2 (en) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성

Also Published As

Publication number Publication date
HRP20150882T1 (hr) 2015-09-25
US8916580B2 (en) 2014-12-23
US20130252962A1 (en) 2013-09-26
CN103664973B (zh) 2017-04-19
US20150291623A1 (en) 2015-10-15
IL212400A (en) 2017-05-29
DK2350090T3 (en) 2015-09-07
JP2012505895A (ja) 2012-03-08
HK1215572A1 (en) 2016-09-02
CY1116628T1 (el) 2017-03-15
NZ592275A (en) 2013-04-26
ES2546302T3 (es) 2015-09-22
US9458178B2 (en) 2016-10-04
HK1219272A1 (zh) 2017-03-31
CN102256983A (zh) 2011-11-23
MY155255A (en) 2015-09-30
CN106928247A (zh) 2017-07-07
EP2350090B1 (en) 2015-06-03
HK1160470A1 (en) 2012-08-17
SI2350090T1 (sl) 2015-10-30
US20120295897A1 (en) 2012-11-22
IL249941A0 (en) 2017-03-30
AR073900A1 (es) 2010-12-09
US8415370B2 (en) 2013-04-09
CN102256983B (zh) 2017-04-05
US20100137299A1 (en) 2010-06-03
CA2741029A1 (en) 2010-04-22
SG10201703086VA (en) 2017-05-30
BRPI0920448A2 (pt) 2018-10-23
PT2350090E (pt) 2015-11-13
KR20110086051A (ko) 2011-07-27
RU2011119626A (ru) 2012-11-27
US8263606B2 (en) 2012-09-11
US20170114075A1 (en) 2017-04-27
AU2009303468A1 (en) 2010-04-22
KR101286323B1 (ko) 2013-07-15
CN105218565A (zh) 2016-01-06
IL212400A0 (en) 2011-06-30
WO2010045251A3 (en) 2010-11-18
PE20110586A1 (es) 2011-09-03
WO2010045251A2 (en) 2010-04-22
EP2942350A1 (en) 2015-11-11
JP2015010090A (ja) 2015-01-19
MX2011004055A (es) 2011-06-24
JO3032B1 (ar) 2016-09-05
AU2009303468B2 (en) 2014-08-28
CN103664973A (zh) 2014-03-26
HK1218294A1 (zh) 2017-02-10
HUE025938T2 (en) 2016-05-30
JP5834104B2 (ja) 2015-12-16
SG10201703082XA (en) 2017-06-29
CL2011000835A1 (es) 2011-07-22
CN105175433A (zh) 2015-12-23
TW201020257A (en) 2010-06-01
EP2350090A2 (en) 2011-08-03
SMT201500206B (it) 2015-10-30
JP5554337B2 (ja) 2014-07-23

Similar Documents

Publication Publication Date Title
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0719803D0 (en) Therapeutic compounds and their use
GB0811304D0 (en) Therapeutic agents
GB0719644D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0811643D0 (en) New therapeutic agents
GB0724251D0 (en) Therapeutic compounds and their use
GB0819593D0 (en) Therapeutic agents
EP2268281A4 (en) THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
GB0722680D0 (en) Therapeutic compounds and their use
GB0801081D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0812913D0 (en) Therapeutic compounds and their use
GB0802128D0 (en) Therapeutic compounds and their use
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0811715D0 (en) Therapeutic agents